5.10 0.00 (0.00%)
After hours: 4:21PM EDT
|Bid||5.10 x 800|
|Ask||5.15 x 1400|
|Day's Range||4.99 - 5.20|
|52 Week Range||4.64 - 51.60|
|Beta (3Y Monthly)||2.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: ...
It’s official: Novavax Inc. will have to complete another clinical trial for its respiratory syncytial virus vaccine candidate for infants, ResVax, lengthening its road to market by roughly three years following its failed phase 3 trial in March. The Gaithersburg biotech has received a letter from the Food and Drug Administration indicating another trial is required before it can earn clearance, said Novavax CEO Stanley Erck in an interview. “We are still heavily focused on RSV,” Erck said, adding: “Yes, it’s going to take a couple years longer and more money than we hoped." The news marks a pivotal moment for Novavax (NASDAQ: NVAX) as it works its way down the regulatory pathways in the U.S. and abroad after ResVax failed to prevent RSV in newborns through maternal immunizations at a high-enough rate in its late-stage trial.
The company will put into effect a reverse stock split of its issued and outstanding common stock, a move intended to increase its share price.
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Nanoflu vaccine updatesOn January 3, Novavax (NVAX) issued a press release announcing positive top-line results from a Phase 2 trial that compared multiple
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Resvax vaccine updatesOn February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM, evaluating the
Is Novavax an Attractive Pick after First-Quarter Results?Stock price movementsNovavax (NVAX) reported first-quarter results on May 2. The company reported revenues of $3.98 billion in the first quarter, a YoY decline of 58.75% and $0.62 million
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
Novavax (NVAX) delivered earnings and revenue surprises of 8.33% and -17.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Gaithersburg, Maryland-based company said it had a loss of 11 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...
Nasdaq has warned Novavax Inc. that its stock could be delisted if it can’t get the price consistently above a buck within the next six months. The Gaithersburg biotech’s stock has fallen below $1 for 30 consecutive days and the company has 180 days — until Oct. 8 — to regain compliance by getting its common stock bid price up for at least 10 consecutive business days. Novavax plans to hold a special stockholder meeting May 8 to consider a reverse stock split, according to public filings.
Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...